[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"subjects-with-mild-hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:subjects-with-mild-hypertension":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100601974","phase-1-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-a-single-subcutaneous-injection-of-hrs-9563-in-subjects-with-mild-hypertension-a-randomized-double-blind-placebo-controlled-phase-i-study-100601974",false,"NCT07117474","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.","Inclusion Criteria:\n\n1. Males or infertile women aged 18-65 years (inclusive);\n2. Body mass index in the range of 19-28 kg\u002Fm2 (inclusive);\n3. Mild primary hypertension, without antihypertensive treatment, with a mean sitting systolic blood pressure ≥ 130 mmHg and ≤ 159 mmHg during screening and baseline, and a mean 24-hour ambulatory systolic blood pressure ≥ 130 mmHg during screening.\n\nExclusion Criteria:\n\n1. Abnormal daily life rhythm;\n2. Any blood biochemical indicator during screening or baseline did not meet the standards in the exclusion criteria;\n3. Secondary hypertension;\n4. Mean sitting diastolic blood pressure ≥ 100 mmHg;\n5. Orthostatic hypotension;\n6. History of type 2 diabetes mellitus or poorly controlled blood glucose;\n7. Recently received any antihypertensive medications or medications that affect blood pressure.",true,"ALL","18 Years","65 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","To evaluate the safety and tolerability of a single subcutaneous injection of HRS-9563 in hypertensive subjects",[27],"Subjects With Mild Hypertension","RECRUITING","2025-08-04",{"date":31,"type":32},"2025-08-12","ACTUAL",{"date":34,"type":32},"2024-12-24",{"date":36,"type":21},"2025-12",{"name":38,"class":39},"Fujian Shengdi Pharmaceutical Co., Ltd.","INDUSTRY"]